Insider Transactions Reported by 5 Insiders of INTERPACE BIOSCIENCES, INC.

Symbol
IDXG on OTC
Location
Parsippany, NJ

Sponsored

Quick Takeaways

  • IDXG - INTERPACE BIOSCIENCES, INC. has 5 insiders with reported activity on this page.
  • No net insider buy/sell flow is currently reported for the last year.
  • Recent transaction rows are available for direct filing-level review.

What Changed

  • No meaningful buy/sell imbalance is currently visible in the one-year window.
  • Activity will update as new Forms 3/4/5 are filed.

Why This Matters

  • This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
  • Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Official SEC Source

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 11 Apr 2025.

Buys

$0

Shares: 0

Insiders: 0

Sells

$0

Shares: 0

Insiders: 0

Net

$0

Shares: 0

Insiders: 0

Window (months) Buy shares Sell shares Buy $ Sell $ Net $
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 0 0 $0 $0 $0
9-12 0 0 $0 $0 $0

INTERPACE BIOSCIENCES, INC. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Ampersand 2018 Limited Partnership 10%+ Owner $27,999,999 Mixed 20 Jan 2026
1315 Capital II, L.P. 10%+ Owner $19,000,000 Mixed 20 Jan 2026
Christopher McCarthy Chief Financial Officer $94,518 Mixed 01 Feb 2024
Thomas W. Burnell President & CEO, Director Mixed 21 May 2021
Vijay Aggarwal Director Mixed 01 Feb 2022

Top shareholders of INTERPACE BIOSCIENCES, INC. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
Ampersand 2018 Limited Partnership
3/4/5
10%+ Owner —
class O/S missing
13,861,386
 $27,999,999 — 20 Jan 2026
3/4/5
1315 Capital II, L.P.
3/4/5
10%+ Owner —
class O/S missing
9,405,941
 $19,000,000 — 20 Jan 2026
3/4/5
Douglas M. Singer
13D/G
—
4.4%
195,742
 $264,252 -$42,260 10 Jan 2025
13D/G
Christopher McCarthy
3/4/5
Chief Financial Officer —
class O/S missing
46,791
 $94,518 — 01 Feb 2024
3/4/5
Thomas W. Burnell
3/4/5
President & CEO, Director —
mixed-class rows
235,855
mixed-class rows
 — — 21 May 2021
3/4/5
Vijay Aggarwal
3/4/5
Director —
class O/S missing
28,000
 — — 01 Feb 2022
3/4/5

Recent Insider Transactions by Companies or Individuals for INTERPACE BIOSCIENCES, INC.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
1315 Capital II, L.P. IDXG Common Stock Conversion of derivative security 9,405,941 9,405,941 20 Jan 2026 Direct
1315 Capital II, L.P. IDXG Series C Convertible Preferred Stock Conversion of derivative security -100% -19,000 0 20 Jan 2026 Direct
Ampersand 2018 Limited Partnership IDXG Common Stock Conversion of derivative security 13,861,386 13,861,386 20 Jan 2026 Direct
Ampersand 2018 Limited Partnership IDXG Series C Convertible Preferred Stock Conversion of derivative security -100% -28,000 0 20 Jan 2026 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Sponsored